Literature DB >> 8171765

Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.

E C de Boer1, T M De Reijke, D H Schamhart, P C Vos, K H Kurth.   

Abstract

This study on the increase in albumin in the urine of patients with superficial bladder cancer after intravesical bacillus Calmette-Guérin (BCG) treatment was initiated on the basis of two facts. First, extravasation of serum albumin could be expected as a result of the BCG-induced delayed-type hypersensitivity reaction in the bladder wall. Second, appearance of albumin in the urine was a possibility as cytokines also appear in the urine, although probably after being produced suburothelially by infiltrating leukocytes. Albumin and the cytokines interleukin (IL)1 beta, IL2, IL6, and tumor necrosis factor alpha (TNF alpha) were determined in urine from 20 patients treated with 6 weekly intravesical BCG instillations, collected prior to each instillation and 2, 4, 6, 8, 12, and 24 h thereafter. The mean concentration of albumin in pre-therapy specimens was 112 +/- 118 (range 2-432) micrograms albumin/ml urine, approximating 14 +/- 14 micrograms/mumol creatinine (creat) (n = 15), which was comparable to the mean pre-instillation value of 16 +/- 32 micrograms/mumol creat (n = 96). A significant increase in urinary albumin during the 6 weeks of BCG treatment was observed (P < 0.001). However, a large variation existed between individual patients and in some patients no reaction was seen. Maximum albumin concentrations were observed after instillations 3-6. A significant correlation between albumin and concentration of the cytokines IL1 beta, IL2, IL6, and TNF alpha was found (P < 0.01), correlation coefficients (r) being 0.56, 0.56, 0.67, and 0.71 (n = 418), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8171765     DOI: 10.1007/bf00300079

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  28 in total

1.  Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma.

Authors:  A Böhle; C Nowc; A J Ulmer; J Musehold; J Gerdes; A G Hofstetter; H D Flad
Journal:  Cytokine       Date:  1990-05       Impact factor: 3.861

2.  Local immune responses after intravesical BCG treatment for carcinoma in situ.

Authors:  M I el-Demiry; G Smith; A W Ritchie; K James; J A Cumming; T B Hargreave; G D Chisholm
Journal:  Br J Urol       Date:  1987-12

3.  Delayed-type hypersensitivity is mediated by a sequence of two different T cell activities.

Authors:  H Van Loveren; P W Askenase
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

4.  Biological response to intravenously administered endotoxin in patients with advanced cancer.

Authors:  R Engelhardt; A Mackensen; C Galanos; R Andreesen
Journal:  J Biol Response Mod       Date:  1990-10

5.  Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy.

Authors:  S Prescott; K James; T B Hargreave; G D Chisholm; J F Smyth
Journal:  J Urol       Date:  1990-11       Impact factor: 7.450

6.  Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability.

Authors:  J M Mullin; K V Snock
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

7.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

8.  A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.

Authors:  R A Badalament; H W Herr; G Y Wong; C Gnecco; C M Pinsky; W F Whitmore; W R Fair; H F Oettgen
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

9.  Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer.

Authors:  T L Ratliff; E O Haaff; W J Catalona
Journal:  Clin Immunol Immunopathol       Date:  1986-08

10.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Authors:  Y Fong; K J Tracey; L L Moldawer; D G Hesse; K B Manogue; J S Kenney; A T Lee; G C Kuo; A C Allison; S F Lowry
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.